{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:43:14Z","timestamp":1792698194623,"version":"4.5.0"},"reference-count":207,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.pharmthera.2009.07.006","type":"journal-article","created":{"date-parts":[[2009,8,16]],"date-time":"2009-08-16T08:12:55Z","timestamp":1250410375000},"page":"39-54","source":"Crossref","is-referenced-by-count":30,"title":["Chemical modification of Class II G protein-coupled receptor ligands: Frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies"],"prefix":"10.1016","volume":"125","author":[{"given":"Megan C.","family":"Chapter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin M.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"DeRidder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Chadwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronwen","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Maudsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2009.07.006_bib1","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/j.1463-1326.2008.00853.x","article-title":"GLP-1: physiological effects and potential therapeutic applications","volume":"10","author":"Aaboe","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib2","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0022-3565(24)38815-9","article-title":"Pharmacology of SB-273779, a nonpeptide calcitonin gene-related peptide 1 receptor antagonist","volume":"296","author":"Aiyar","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib3","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1210\/en.2004-1044","article-title":"Partial reversibility of growth hormone (GH) deficiency in the GH-releasing hormone (GHRH) knockout mouse by postnatal treatment with a GHRH analog","volume":"146","author":"Alba","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib4","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/298240a0","article-title":"Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products","volume":"298","author":"Amara","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/joe.0.1600001","article-title":"The role of corticotropin-releasing factor in depression and anxiety disorders","volume":"160","author":"Arborelius","year":"1999","journal-title":"J Endocrinol"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib6","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/nn1419","article-title":"Vasoactive intestinal polypeptide mediates circadian rhythmicity and synchrony in mammalian clock neurons","volume":"8","author":"Aton","year":"2005","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib7","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1124\/jpet.102.036129","article-title":"Differential transport of a secretin analog across the blood-brain and blood-cerebrospinal fluid barriers of the mouse","volume":"302","author":"Banks","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib8","first-page":"371","article-title":"Localization of glucagon in the alpha cells in the pancreatic islet by immunofluorescent technics","volume":"11","author":"Baum","year":"1962","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib9","first-page":"5","article-title":"Adrenomedullin\u2014what do we know 10years since its discovery?","volume":"56","author":"Beltowski","year":"2004","journal-title":"Pol J Pharmacol"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib10","doi-asserted-by":"crossref","first-page":"E751","DOI":"10.1152\/ajpendo.90295.2008","article-title":"Insulin as a physiological modulator of glucagon secretion","volume":"295","author":"Bensal","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib11","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1001\/jama.254.21.3067","article-title":"Corticotropin-releasing factor-like immunoreactivity in senile dementia of the Alzheimer type. Reduced cortical and striatal concentrations","volume":"254","author":"Bissette","year":"1985","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib12","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s11064-008-9646-4","article-title":"Glucagon-like peptide-1 (GLP-1) diminishes neuronal degeneration and death caused by NGF deprivation by suppressing Bim induction","volume":"33","author":"Biswas","year":"2008","journal-title":"Neurochem Res"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib13","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.peptides.2008.01.022","article-title":"Novel stable PACAP analogs with potent activity towards the PAC1 receptor","volume":"29","author":"Bourgault","year":"2008","journal-title":"Peptides"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib14","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1152\/physrev.00037.2003","article-title":"Vascular actions of calcitonin gene-related peptide and adrenomedullin","volume":"84","author":"Brain","year":"2004","journal-title":"Physiol Rev"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib15","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1073\/pnas.83.4.1159","article-title":"Vasoactive intestinal peptide and electrical activity influence neuronal survival","volume":"83","author":"Brenneman","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib16","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1152\/jn.01206.2006","article-title":"Disrupted neuronal activity rhythms in the suprachiasmatic nuclei of vasoactive intestinal polypeptide-deficient mice","volume":"97","author":"Brown","year":"2007","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib17","doi-asserted-by":"crossref","first-page":"2534S","DOI":"10.1093\/jn\/137.11.2534S","article-title":"Glucagon-like peptide-1 and energy homeostasis","volume":"137","author":"Burcelin","year":"2007","journal-title":"J Nutr"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib18","doi-asserted-by":"crossref","first-page":"7665","DOI":"10.4049\/jimmunol.174.12.7665","article-title":"Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor","volume":"174","author":"Cao","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00726-007-0567-3","article-title":"Experimental study on vasoactive intestinal peptide (VIP) and its diaminopropane bound (VIP-DAP) analog in solution","volume":"35","author":"Caraglia","year":"2008","journal-title":"Amino Acids"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib20","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0026-895X(25)09159-X","article-title":"Pituitary adenylate cyclase activating polypeptide prevents apoptosis in cultured cerebellar granule neurons","volume":"50","author":"Cavallaro","year":"1996","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0024-3205(96)00258-5","article-title":"[MPR14]-rADM (14\u201350), a novel analog of adrenomedullin possesses potent vasodilator activity in the hindlimb vascular bed of the cat","volume":"59","author":"Champion","year":"1996","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib22","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1210\/en.139.7.3357","article-title":"A corticotrophin-releasing hormone Type I receptor antagonist delays parturition in sheep","volume":"139","author":"Chan","year":"1998","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib23","doi-asserted-by":"crossref","first-page":"8967","DOI":"10.1073\/pnas.90.19.8967","article-title":"Expression and cloning of a human corticotropin-releasing factor receptor","volume":"90","author":"Chen","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib24","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1021\/jm960149e","article-title":"Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor(1) receptor antagonists","volume":"39","author":"Chen","year":"1996","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib25","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/jps.21524","article-title":"Synthesis, characterization and in vivo activity of salmon calcitonin coconjugated with lipid and polyethylene glycol","volume":"98","author":"Cheng","year":"2009","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.regpep.2006.12.020","article-title":"Study on preparation and activity of a novel recombinant human parathyroid hormone(1\u201334) analog with N-terminal Pro-Pro extension","volume":"141","author":"Chunxiao","year":"2007","journal-title":"Regul Pept"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1699-0463.1996.tb00680.x","article-title":"Islet amyloid in type 2 (non-insulin-dependent) diabetes","volume":"104","author":"Clark","year":"1996","journal-title":"APMIS"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib28","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/sj.bjp.0704378","article-title":"Parathyroid hormone-related protein and its receptors: nuclear functions and roles in the renal and cardiovascular systems, the placental trophoblasts and the pancreatic islets","volume":"134","author":"Clemens","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.regpep.2006.02.010","article-title":"Novel extended and branched N-terminal analogs of VIP","volume":"137","author":"Dangoor","year":"2006","journal-title":"Regul Pept"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib30","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.peptides.2007.03.014","article-title":"Novel analogs of VIP with multiple C-terminal domains","volume":"28","author":"Dangoor","year":"2007","journal-title":"Peptides"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/psc.932","article-title":"Novel glycosylated VIP analogs: synthesis, biological activity, and metabolic stability","volume":"14","author":"Dangoor","year":"2008","journal-title":"J Pept Sci"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib32","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1189\/jlb.1203626","article-title":"VIP\/PACAP oppositely affects immature and mature dendritic cell expression of CD80\/CD86 and the stimulatory activity for CD4(+) T cells","volume":"75","author":"Delgado","year":"2004","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib33","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/glia.20681","article-title":"Vasoactive intestinal peptide protects against beta-amyloid-induced neurodegeneration by inhibiting microglia activation at multiple levels","volume":"56","author":"Delgado","year":"2008","journal-title":"Glia"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib34","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2337\/diacare.29.02.06.dc05-2043","article-title":"Exenatide (exendin-4)-induced pancreatitis. A case report","volume":"29","author":"Denker","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib35","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1016\/j.peptides.2006.05.011","article-title":"Effects of glucose-dependent insulinotropic peptide on behavior","volume":"27","author":"Ding","year":"2006","journal-title":"Peptides"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib36","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11102-006-0410-y","article-title":"Growth hormone deficiency in the adult","volume":"9","author":"Doga","year":"2006","journal-title":"Pituitary"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib37","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2337\/diabetes.47.2.159","article-title":"Glucagon-like peptides","volume":"47","author":"Drucker","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0165-0173(90)90012-D","article-title":"Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses?","volume":"15","author":"Dunn","year":"1990","journal-title":"Brain Res Brain Res Rev"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib39","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0303-7207(98)00096-3","article-title":"Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression","volume":"141","author":"Dunphy","year":"1998","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib40","doi-asserted-by":"crossref","first-page":"4S","DOI":"10.1177\/0145721707313939","article-title":"Optimizing diabetes treatment using an amylin analogue","volume":"34","author":"Edelman","year":"2008","journal-title":"The Diabetes Educator"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib41","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1046\/j.0022-3042.2001.00712.x","article-title":"Potential signalling pathways underlying corticotrophin-releasing hormone-mediated neuroprotection from excitotoxicity in rat hippocampus","volume":"80","author":"Elliott-Hunt","year":"2002","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib42","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/bip.20030","article-title":"The biological potency of a series of analogues of human calcitonin correlates with their interactions with phospholipids","volume":"76","author":"Epand","year":"2004","journal-title":"Biopolymers"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib43","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/07420520500464569","article-title":"PACAP\u2014a multifaceted neuropeptide","volume":"23","author":"Fahrenkrug","year":"2006","journal-title":"Chronobiol Int"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib44","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/j.1464-5491.2005.01567.x","article-title":"Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with type 2 diabetes","volume":"22","author":"Feinglos","year":"2005","journal-title":"Diabetic Medicine"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib45","first-page":"G901","article-title":"Chief cells possess a receptor with high affinity for PACAP and VIP that stimulates pepsinogen release","volume":"263","author":"Felley","year":"1992","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib46","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1523\/JNEUROSCI.03-08-01620.1983","article-title":"Secretin: specific binding to rat brain membranes","volume":"3","author":"Fremeau","year":"1983","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib47","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1046\/j.1468-2982.1995.1505384.x","article-title":"Vasoactive peptides levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally","volume":"15","author":"Gallai","year":"1995","journal-title":"Cephalalgia"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib48","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1016\/j.bcp.2008.03.011","article-title":"C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes","volume":"75","author":"Gault","year":"2008","journal-title":"Biochem Pharmacol"},{"issue":"Suppl 2","key":"10.1016\/j.pharmthera.2009.07.006_bib49","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/S1262-3636(08)73397-4","article-title":"Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes","volume":"34","author":"Gautier","year":"2008","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib50","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1210\/me.2003-0275","article-title":"Identification of a contact site for residue 19 of parathyroid hormone (PTH) and PTH-related protein analogs in transmembrane domain two of the type 1 PTH receptor","volume":"17","author":"Gensure","year":"2003","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib51","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2174\/187153008784534367","article-title":"Growth hormone and insulin-like growth factor-I as an endocrine axis in Alzheimer's disease","volume":"8","author":"G\u00f3mez","year":"2008","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib52","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0306-4522(96)00617-3","article-title":"Pituitary adenylate cyclase-activating polypeptide promotes cell survival and neurite outgrowth in rat cerebellar neuroblasts","volume":"78","author":"Gonzalez","year":"1997","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib53","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.2174\/138161207780618966","article-title":"Therapeutic approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator","volume":"13","author":"Gonzalez-Rey","year":"2007","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib54","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1210\/endo-114-4-1187","article-title":"Characterization of insulin-like growth factor receptors in rat anterior pituitary, hypothalamus, and brain","volume":"114","author":"Goodyer","year":"1984","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib55","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1043-2760(02)00670-7","article-title":"Functional characteristics of CRH receptors and potential clinical application of CRH-receptor antagonists","volume":"13","author":"Grammatopoulos","year":"2002","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib56","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1210\/en.2002-220401","article-title":"Temperature sensitive phenotype in mice lacking pituitary adenylate cyclase activating polypeptide","volume":"143","author":"Gray","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib57","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.beem.2007.09.003","article-title":"Incretin hormone mimetics and analogues in diabetes","volume":"21","author":"Green","year":"2007","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib58","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0006-8993(97)01011-1","article-title":"Effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on corticotrophin-releasing hormone (CRH) gene expression in the rat hypothalamic paraventricular nucleus","volume":"773","author":"Grinevich","year":"1997","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib59","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.regpep.2004.07.019","article-title":"GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice","volume":"128","author":"Hansotia","year":"2005","journal-title":"Regul Pept"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib60","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.neuroscience.2008.07.034","article-title":"Transgenic overexpression of corticotropin releasing hormone provides partial protection against neurodegeneration in an in vivo model of acute excitotoxic stress","volume":"156","author":"Hanstein","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib61","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0092-8674(02)00736-5","article-title":"The VPAC(2) receptor is essential for circadian function in the mouse suprachiasmatic nuclei","volume":"109","author":"Harmar","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib62","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/0196-9781(93)90174-F","article-title":"Parathyroid hormone binding sites in the brain","volume":"14","author":"Harvey","year":"1993","journal-title":"Peptides"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib63","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1248\/yakushi.122.1109","article-title":"Physiological significance of pituitary adenylate cyclase-activating polypeptide (PACAP) in the nervous system","volume":"122","author":"Hashimoto","year":"2002","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib64","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/sj.mp.4001982","article-title":"Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia","volume":"12","author":"Hashimoto","year":"2007","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib65","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0197-4580(92)90037-X","article-title":"Growth hormone secretion in Alzheimer's disease: 24-hour profile of basal levels and response to stimulation and suppression studies","volume":"13","author":"Heuser","year":"1992","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib66","first-page":"284","article-title":"Conditioned fear freezing behavior suppression treated by CRH1 receptor antagonist","volume":"17","author":"Hikichi","year":"1997","journal-title":"Jpn J Psychopharm"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib67","first-page":"278","article-title":"Blockade of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry","volume":"33","author":"Hill","year":"2007","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib68","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/sj.bjp.0702949","article-title":"Adverse effects of an active fragment of parathyroid hormone on rat hippocampal organotypic cultures","volume":"129","author":"Hirasawa","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib69","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1210\/edrv-17-2-187","article-title":"Antidepressants and hypothalamic-pituitary-adrenocortical regulation","volume":"17","author":"Holsboer","year":"1996","journal-title":"Endocr Rev"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib70","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.2174\/0929867033456648","article-title":"Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus","volume":"10","author":"Holz","year":"2003","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib71","first-page":"9","article-title":"Improved social and language skills after secretin administration in patients with autistic spectrum disorders","volume":"9","author":"Horvath","year":"1998","journal-title":"J Assoc Acad Minor Phys"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib72","first-page":"33","article-title":"Molecular physiology and pharmacology of calcitonin","volume":"52","author":"Huang","year":"2006","journal-title":"Cell Mol Biol"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib73","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1210\/jc.2006-1702","article-title":"Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog","volume":"91","author":"Ionescu","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-0115(00)00232-9","article-title":"Molecular evolution of proglucagon","volume":"98","author":"Irwin","year":"2001","journal-title":"Regul Pept"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib75","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1124\/jpet.105.086082","article-title":"A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes","volume":"314","author":"Irwin","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib76","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1054\/npep.2000.0806","article-title":"Effect of corticotrophin releasing factor receptor 1 antagonist on extracellular norepinephrine, dopamine and serotonin in hippocampus and prefrontal cortex of rats in vivo","volume":"34","author":"Isogawa","year":"2000","journal-title":"Neuropeptides"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib77","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1073\/pnas.92.11.4872","article-title":"Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone","volume":"92","author":"Izdebski","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib78","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1523\/JNEUROSCI.1051-04.2004","article-title":"Antagonist of the amylin receptor blocks beta-amyloid toxicity in rat cholinergic basal forebrain neurons","volume":"24","author":"Jhamanadas","year":"2004","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib79","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1385\/JMN:18:1-2:07","article-title":"Interactions of glucagon-like peptide-1 (GLP-1) with the blood brain barrier","volume":"18","author":"Kastin","year":"2002","journal-title":"J Mol Neurosci"},{"issue":"Suppl 1","key":"10.1016\/j.pharmthera.2009.07.006_bib80","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1291\/hypres.26.S113","article-title":"Adrenomedullin: a possible autocrine or paracrine hormone in the cardiac ventricles","volume":"26","author":"Kato","year":"2003","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib81","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1152\/ajpcell.00504.2004","article-title":"Immature osteoblastic MG63 cells possess two calcitonin gene-related peptide receptor subtypes that respond differently to [Cys(Acm)2, 7] calcitonin gene-related peptide and CGRP8-37","volume":"289","author":"Kawase","year":"2005","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib82","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1517\/14656566.5.2.379","article-title":"The effectiveness of secretin in the management of autism","volume":"5","author":"Kern","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib83","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/sj.neo.7900074","article-title":"Antagonists of growth hormone-releasing hormone inhibit the growth of U-87MG human glioblastoma in nude mice","volume":"2","author":"Kiaris","year":"2000","journal-title":"Neoplasia"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib84","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1073\/pnas.97.2.532","article-title":"Antitumorigenic actions of growth hormone-releasing hormone antagonists","volume":"97","author":"Kineman","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib85","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1006\/bbrc.1993.1451","article-title":"Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma","volume":"192","author":"Kitamura","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib86","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s00198-004-1798-8","article-title":"Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials","volume":"16","author":"Knopp","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib87","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1021\/jm9909645","article-title":"Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration","volume":"43","author":"Knudsen","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib88","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1073\/pnas.0605701104","article-title":"Small-molecule agonists for the glucagon-like peptide 1 receptor","volume":"104","author":"Knudsen","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib89","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1210\/endo-127-1-264","article-title":"Immunohistochemical demonstration of a novel hypothalamic peptide, pituitary adenylate cyclase-activating polypeptide, in the ovine hypothalamus","volume":"127","author":"K\u00f6ves","year":"1990","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib90","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/014572179902500310","article-title":"Clinical implications of amylin and amylin deficiency","volume":"25","author":"Kruger","year":"1999","journal-title":"Diabetes Educ"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib91","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1097\/01.wnr.0000134849.63755.15","article-title":"Tuberoinfundibular peptide of 39 residues decreases pain-related affective behavior","volume":"15","author":"LaBuda","year":"2004","journal-title":"Neuroreport"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib92","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/BF03345237","article-title":"Ageing, growth hormone and physical performance","volume":"26","author":"Lanfranco","year":"2003","journal-title":"J Encrinol Invest"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib93","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/BF03345237","article-title":"Ageing, growth hormone and physical performance","volume":"26","author":"Lanfranco","year":"2003","journal-title":"J Encrinol Invest"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib94","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.peptides.2008.02.017","article-title":"Pharmacologic study of C-terminal fragments of frog skin calcitonin gene-related peptide","volume":"29","author":"Ladram","year":"2008","journal-title":"Peptides"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib95","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1365-2265.2004.02164.x","article-title":"The impact of idiopathic childhood-onset growth hormone deficiency (GHD) on bone mass in subjects without adult GHD","volume":"62","author":"Lange","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib96","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.peptides.2003.12.013","article-title":"Hexanoylation of a VPAC2 receptor-preferring ligand markedly increased its selectivity and potency","volume":"25","author":"Langer","year":"2004","journal-title":"Peptides"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib97","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/j.peptides.2004.08.017","article-title":"Comparative efficacy of VIP and analogs on activation and internalization of the recombinant VPAC2 receptor expressed in CHO cells","volume":"25","author":"Langlet","year":"2004","journal-title":"Peptides"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib98","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10194-008-0036-8","article-title":"Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients","volume":"9","author":"Lassen","year":"2008","journal-title":"J Headache Pain"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib99","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1021\/bc049735+","article-title":"Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1","volume":"16","author":"Lee","year":"2005","journal-title":"Bioconjugate Chem"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib100","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ydbio.2007.10.031","article-title":"Disruption of the PACAP gene promotes medulloblastoma in ptc1 mutant mice","volume":"313","author":"Lelievre","year":"2008","journal-title":"Dev Biol"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib101","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0165-1781(90)90063-B","article-title":"Endocrine responses to growth hormone releasing hormone and corticotrophin releasing hormone in early-onset Alzheimer's disease","volume":"33","author":"Lesch","year":"1990","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib102","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1210\/me.14.1.147","article-title":"Corticotropin-releasing hormone-mediated neuroprotection against oxidative stress is associated with the increased release of non-amyloidogenic amyloid beta precursor protein and with the suppression of nuclear factor-kappaB","volume":"14","author":"Lezoualc'h","year":"2000","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib103","doi-asserted-by":"crossref","unstructured":"Li, S., Grinevich, V., Fournier, A., & Pelletier, G. (1996). Effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on gonadotropin-releasing hormone and somatostatin gene expression in the rat brain. Mol Brain Res 41, 157\u2013162.","DOI":"10.1016\/0169-328X(96)00086-1"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib104","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1210\/en.137.1.72","article-title":"Cloning and characterization of the human corticotropin-releasing factor-2 receptor complementary deoxyribonucleic acid","volume":"137","author":"Liaw","year":"1996","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib105","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/01.ajp.0000210954.93878.0d","article-title":"Involvement of intra-ocular corticotropin-releasing hormone in postoperative pain modulation","volume":"23","author":"Likar","year":"2007","journal-title":"Clin J Pain"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib106","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000140676","article-title":"Vasoactive intestinal polypeptide is critical for circadian regulation of glucocorticoids","volume":"88","author":"Loh","year":"2008","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib107","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.mehy.2007.12.011","article-title":"Peptic ulceration may be a hormonal deficiency disease","volume":"70","author":"Love","year":"2008","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib108","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1073\/pnas.79.2.345","article-title":"Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem","volume":"79","author":"Lund","year":"1982","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib109","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000127113","article-title":"Evidence for the presence of receptors for pituitary adenylate cyclase-activating polypeptide in the neurohypophysis that are positively coupled to cyclic AMP formation and neurohypophyseal hormone secretion","volume":"64","author":"Lutz-Bucher","year":"1996","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib110","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1152\/ajpregu.00001.2003","article-title":"PTHrP regulates cerebral blood flow and is neuroprotective","volume":"284","author":"Macica","year":"2003","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib111","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/S0021-9258(18)69179-3","article-title":"Vasoactive intestinal polypeptide and muscarine mobilize intracellular Ca2+ through breakdown of phosphoinositides to induce catecholamine secretion. Role of IP3 in exocytosis","volume":"263","author":"Malhotra","year":"1988","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib112","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0378-1119(90)90362-U","article-title":"Structure of the mouse gene encoding parathyroid hormone-related protein","volume":"95","author":"Mangin","year":"1990","journal-title":"Gene"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib113","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1385\/NMM:7:1-2:003","article-title":"Class II G protein-coupled receptors and their ligands in neuronal function and protection","volume":"7","author":"Martin","year":"2005","journal-title":"Neuromolec Med"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib114","first-page":"237","article-title":"Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body","volume":"23","author":"Martin","year":"2008","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib115","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2337\/db08-0799","article-title":"Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies and extends survival in a mouse model of Huntington's disease","volume":"58","author":"Martin","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib116","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0006-8993(92)90430-H","article-title":"Binding sites for pituitary adenylate cyclase activating polypeptide (PACAP): comparison with vasoactive intestinal polypeptide (VIP) binding site localization in rat brain sections","volume":"575","author":"Masuo","year":"1992","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib117","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.arr.2004.08.001","article-title":"A neural signaling triumvirate that influences ageing and age-related disease: insulin\/IGF-1, BDNF and serotonin","volume":"3","author":"Mattson","year":"2004","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib118","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1124\/jpet.105.083121","article-title":"The origins of diversity and specificity in G protein-coupled receptor signaling","volume":"314","author":"Maudsley","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib119","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/306086a0","article-title":"Expression-cloning and sequence of a cDNA encoding human growth hormone-releasing factor","volume":"306","author":"Mayo","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib120","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0196-9781(84)90265-1","article-title":"Corticotropin releasing factor (CRF)-like immunoreactivity in the rat central nervous system. Extrahypothalamic distribution","volume":"5","author":"Merchenthaler","year":"1984","journal-title":"Peptides"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib121","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1210\/endo-114-4-1082","article-title":"Immunocytochemical localization of growth hormone-releasing factor in the rat hypothalamus","volume":"114","author":"Merchenthaler","year":"1984","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib122","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1530\/rep.0.1210493","article-title":"Corticotropin-releasing hormone and human parturition","volume":"121","author":"McLean","year":"2001","journal-title":"Reproduction"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib123","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1345\/aph.19113","article-title":"Secretin for the treatment of autism","volume":"36","author":"McQueen","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib124","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1210\/er.2003-0002","article-title":"Gonadotropin-releasing hormone receptors","volume":"25","author":"Millar","year":"2004","journal-title":"Endocr Rev"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib125","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0006-291X(89)91757-9","article-title":"Isolation of a novel 38 residue-hypothalamic polypeptide which stimulate adenylate cyclase in pituitary cells","volume":"164","author":"Miyata","year":"1989","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib126","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1159\/000126475","article-title":"Pituitary adenylate cyclase-activating polypeptide stimulates arginine vasopressin release in conscious rats","volume":"57","author":"Murase","year":"1993","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib127","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1042\/bst0080011","article-title":"Chemistry, isolation and purification of gastrointestinal hormones","volume":"8","author":"Mutt","year":"1980","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib128","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1159\/000125296","article-title":"Growth hormone response to growth hormone releasing factor in Alzheimer's disease","volume":"50","author":"Nemeroff","year":"1989","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib129","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1093\/hmg\/ddl402","article-title":"Secretin receptor-deficient mice exhibit impaired synaptic plasticity and social behavior","volume":"15","author":"Nishijima","year":"2006","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib130","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2174\/1568016054368241","article-title":"Cardiac adrenomedullin: its role in cardiac hypertrophy and heart failure","volume":"3","author":"Nishikimi","year":"2005","journal-title":"Curr Med Chem Cardiovasc Hematol Agents"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib131","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1523\/JNEUROSCI.4920-04.2005","article-title":"Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation","volume":"25","author":"Nyberg","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib132","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/jnr.21349","article-title":"Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain","volume":"85","author":"Nyberg","year":"2007","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib133","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1177\/0145721706294003","article-title":"Update in the pharmacologic treatment of Diabetes Mellitus: focus on pramlintide and exentide","volume":"32","author":"Odegard","year":"2006","journal-title":"Diabetes Educator"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib134","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0006-8993(99)02375-6","article-title":"Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease","volume":"854","author":"Offen","year":"2000","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib135","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1152\/ajpendo.00391.2006","article-title":"Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob\/ob mice","volume":"292","author":"O'Hartem","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib136","first-page":"66","article-title":"Parathyroid disorders and bone metabolism","volume":"15","author":"Okazaki","year":"2005","journal-title":"Clin Calcim"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib137","doi-asserted-by":"crossref","first-page":"16525","DOI":"10.1073\/pnas.0808750105","article-title":"Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation","volume":"105","author":"Okazaki","year":"2008","journal-title":"PNAS"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib138","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.peptides.2007.04.009","article-title":"Bioactive analogues and drug delivery systems of vasoactive intestinal peptide (VIP) for the treatment of asthma\/COPD","volume":"28","author":"Onoue","year":"2007","journal-title":"Peptides"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib139","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00210-007-0232-0","article-title":"Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications","volume":"377","author":"Onoue","year":"2008","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib140","first-page":"135","article-title":"Role of amylin in glucose homeostasis and its perspective use in diabetes management","volume":"65","author":"Otto-Buczkowska","year":"2008","journal-title":"Przegl Lek"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib141","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0031-6997(25)06673-6","article-title":"Physiology and pharmacology of corticotrophin-releasing factor","volume":"43","author":"Owens","year":"1991","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib142","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/ng0592-149","article-title":"A donor splice site mutation in the parathyroid hormone gene is associated with autosomal recessive hypoparathyroidism","volume":"1","author":"Parkinson","year":"1992","journal-title":"Nat Genet"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib143","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1592\/phco.22.11.905.33622","article-title":"Secretin treatment for autistic disorder: a critical analysis","volume":"22","author":"Patel","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib144","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1006\/nbdi.2001.0395","article-title":"Corticotropin-releasing hormone protects neurons against insults relevant to the pathogenesis of Alzheimer's disease","volume":"8","author":"Pedersen","year":"2001","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib145","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.coph.2005.07.004","article-title":"Parathyroid hormone \u2013 a bone anabolic and catabolic agent","volume":"5","author":"Poole","year":"2005","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib146","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/0006-3223(89)90071-1","article-title":"CSF corticotropin-releasing factor (CRF) in Alzheimer's disease: its relationship to severity of dementia and monoamine metabolites","volume":"26","author":"Pomara","year":"1989","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib147","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1900\/RDS.2008.5.73","article-title":"Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors","volume":"5","author":"Pratley","year":"2008","journal-title":"Rev Diabet Stud"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib148","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.mehy.2007.08.024","article-title":"Calcitonin may be a useful therapeutic agent for osteoclastogenesis syndromes involving premature eruption of the tooth","volume":"70","author":"Qin","year":"2008","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib149","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1046\/j.0953-816x.2000.01437.x","article-title":"Vasoactive intestinal polypeptide (VIP) phase-shifts the rat suprachiasmatic nucleus clock in vitro","volume":"13","author":"Reed","year":"2001","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib150","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/S0196-9781(02)00262-0","article-title":"Effects of pretreatment with PACAP on the infarct size and functional outcome in rat permanent focal cerebral ischemia","volume":"23","author":"Reglodi","year":"2002","journal-title":"Peptides"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib151","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.npep.2006.06.001","article-title":"Effect of PACAP in 6-OHDA-induced injury of the substantia nigra in intact young and ovariectomized female rats","volume":"40","author":"Regl\u00f6di","year":"2006","journal-title":"Neuropeptides"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib152","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1749-6632.1988.tb26998.x","article-title":"Neuroendocrine significance of vasoactive intestinal polypeptide","volume":"527","author":"Reichlin","year":"1988","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib153","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1210\/en.141.6.2120","article-title":"Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers","volume":"141","author":"Rekasi","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib154","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/00365529309098234","article-title":"The mediators of bile action on the exocrine pancreas","volume":"28","author":"Riepl","year":"1993","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib155","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1046\/j.1460-9568.1998.00064.x","article-title":"Evidence for the involvement of corticotrophin-releasing hormone in the pathogenesis of traumatic brain injury","volume":"10","author":"Roe","year":"1998","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib156","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1210\/endo-114-5-1571","article-title":"Characterization of high affinity receptors for insulin-like growth factors I and II on rat anterior pituitary cells","volume":"114","author":"Rosenfeld","year":"1984","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib157","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/cne.902370108","article-title":"The distribution of growth-hormone-releasing factor (GRF) immunoreactivity in the central nervous system of the rat: an immunohistochemical study using antisera directed against rat hypothalamic GRF","volume":"237","author":"Sawchenko","year":"1985","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib158","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.2337\/diabetes.53.suppl_3.S233","article-title":"Amylin agonists: a novel approach in the treatment of diabetes","volume":"53","author":"Schmitz","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib159","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ygcen.2004.12.018","article-title":"The GRAFS classification system of G protein coupled receptors in comparative perspective","volume":"142","author":"Schi\u00f6th","year":"2005","journal-title":"Gen Comp Endocrinol"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib160","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0014-2999(95)00011-9","article-title":"The effects of pituitary adenylate cyclase-activating polypeptide on cerebral arteries and vertebral artery blood flow in anesthetized dogs","volume":"275","author":"Seki","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib161","doi-asserted-by":"crossref","first-page":"C114","DOI":"10.1152\/ajpcell.00566.2005","article-title":"Role of calcium channels in carboxyl-terminal parathyroid hormone receptor signaling","volume":"291","author":"Selim","year":"2006","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib162","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/jps.21116","article-title":"Dimerization of PACAP peptide analogue in DMSO via asparagine and aspartic acid residues","volume":"97","author":"Severs","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib163","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1210\/er.21.6.619","article-title":"The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)\/glucagon superfamily","volume":"21","author":"Sherwood","year":"2000","journal-title":"Endocr Rev"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib164","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1210\/jcem-63-1-167","article-title":"Studies on the response of growth hormone (GH) secretion to GH-releasing hormone, thyrotropin-releasing hormone, gonadotropin-releasing hormone, and somatostatin in acromegaly","volume":"63","author":"Shibasaki","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib165","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1359\/jbmr.040914","article-title":"Amino-terminal parathyroid hormone fragment analogs containing alpha, alpha-di-alkyl amino acids at positions 1 and 3","volume":"19","author":"Shimizu","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib166","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1471-4159.2008.05397.x","article-title":"Modulation of taste sensitivity by GLP-1 signaling","volume":"106","author":"Shin","year":"2008","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib167","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0167-0115(02)00169-6","article-title":"Defects in reproductive functions in PACAP-deficient female mice","volume":"109","author":"Shintani","year":"2002","journal-title":"Regul Pept"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib168","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1046\/j.1365-2362.1999.00440.x","article-title":"Comparison of the effect of native glucagon-like peptide 1 and dipeptidyl peptidase IV-resistant analogues on insulin release from rat pancreatic islets","volume":"29","author":"Siegel","year":"1999","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib169","first-page":"962","article-title":"Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 9. Calcitonin in the treatment of osteoporosis","volume":"155","author":"Siminoski","year":"1996","journal-title":"CMAJ"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib170","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.2174\/1381612043383548","article-title":"Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide","volume":"10","author":"Somogyv\u00e1ri-Vigh","year":"2004","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib171","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1523\/JNEUROSCI.12-12-04923.1992","article-title":"Vasoactive intestinal peptide and noradrenaline exert long-term control on glycogen levels in astrocytes: blockade by protein synthesis inhibition","volume":"12","author":"Sorg","year":"1992","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib172","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1046\/j.1432-1033.2002.03278.x","article-title":"Monitoring the structural consequences of Phe12\u2192d-Phe and Leu15\u2192Aib substitution in human\/rat corticotropin releasing hormone. Implications for design of CRH antagonists","volume":"269","author":"Spyroulias","year":"2002","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib173","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.mehy.2005.02.036","article-title":"Do vasoactive neuropeptide autoimmune disorders explain pyridostigmine's association with Gulf War syndrome?","volume":"65","author":"Staines","year":"2005","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib174","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.mehy.2007.04.004","article-title":"Is Parkinson's disease an autoimmune disorder of endogenous vasoactive neuropeptides?","volume":"69","author":"Staines","year":"2007","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib175","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.mehy.2007.04.038","article-title":"Are multiple sclerosis and amyotrophic lateral sclerosis autoimmune disorders of endogenous vasoactive neuropeptides?","volume":"70","author":"Staines","year":"2008","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib176","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/sj.npp.1300487","article-title":"Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats","volume":"30","author":"Stinus","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib177","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1055\/s-2003-45132","article-title":"Stress responsive neurohormones in depression and anxiety","volume":"36","author":"Str\u00f6hle","year":"2003","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib178","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0303-7207(94)90162-7","article-title":"Relative quantitative analysis of glucagon receptor mRNA in rat tissues","volume":"105","author":"Svoboda","year":"1994","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib179","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/cne.902850402","article-title":"Differential steroid hormone and neural influences on peptide mRNA levels in CRH cells of the paraventricular nucleus: a hybridization histochemical study in the rat","volume":"285","author":"Swanson","year":"1989","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib180","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1210\/jc.2005-1536","article-title":"Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults","volume":"91","author":"Teichman","year":"2006","journal-title":"J Clin Endocrin and Metab"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib181","first-page":"215","article-title":"Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging","volume":"52","author":"Thorner","year":"1997","journal-title":"Recent Prog Horm Res"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib182","doi-asserted-by":"crossref","first-page":"37787","DOI":"10.1074\/jbc.M106692200","article-title":"A small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-terminal hormone binding domain","volume":"276","author":"Tibaduiza","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib183","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/14724","article-title":"TIP39: a new neuropeptide and PTH2-receptor agonist from hypothalamus","volume":"2","author":"Usdin","year":"1999","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib184","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1126\/science.6267699","article-title":"Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotrophin and beta-endorphin","volume":"213","author":"Vale","year":"1981","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib185","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1073\/pnas.96.2.692","article-title":"Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities","volume":"96","author":"Varga","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib186","doi-asserted-by":"crossref","first-page":"13390","DOI":"10.1073\/pnas.97.24.13390","article-title":"The neuroprotective effect of pituitary adenylate cyclase-activating polypeptide on cerebellar granule cells is mediated through inhibition of the CED3-related cysteine protease caspase-3\/CPP32","volume":"97","author":"Vaudry","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib187","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1210\/jc.86.4.1489","article-title":"Middle-aged men show higher sensitivity of sleep to the arousing effects of corticotropin-releasing hormone than young men: clinical implications","volume":"86","author":"Vgontzas","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib188","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1523\/JNEUROSCI.17-01-00083.1997","article-title":"Pituitary adenylate cyclase-activating polypeptide (PACAP-38) protects cerebellar granule neurons from apoptosis by activating the mitogen-activated protein kinase (MAP kinase) pathway","volume":"17","author":"Villalba","year":"1997","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib189","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0167-0115(03)00111-3","article-title":"Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects","volume":"114","author":"Vilsb\u00f8ll","year":"2003","journal-title":"Regul Pept"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib190","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1210\/jc.2003-030738","article-title":"The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype","volume":"88","author":"Vilsb\u00f8ll","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib191","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000119395","article-title":"Defective 5-HT 1-receptor-mediated neurotransmission in the control of growth hormone secretion in Parkinson's disease","volume":"35","author":"Volpi","year":"1997","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib192","first-page":"121","article-title":"Incretin levels in polycystic ovary syndrome","volume":"159","author":"Vrbikova","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib193","doi-asserted-by":"crossref","DOI":"10.1677\/JME-09-0023","article-title":"Interactions of ghrelin signaling pathways with the growth hormone neuroendocrine axis: a new and experimentally tested model","author":"Wagner","year":"2009","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib194","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1517\/14656560802611832","article-title":"Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus","volume":"10","author":"Wajcberg","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib195","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0955-2863(02)00181-X","article-title":"Regulation mechanisms of intestinal secretion: implications in nutrient absorption","volume":"13","author":"Wapnir","year":"2002","journal-title":"J Nutr Biochem"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib196","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/0169-328X(94)00222-Z","article-title":"Localization of parathyroid hormone-related peptide (PTHrP) and PTH\/PTHrP receptor mRNAs in rat brain","volume":"28","author":"Weaver","year":"1995","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib197","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1073\/pnas.87.1.108","article-title":"Parathyroid hormone-related peptide gene is expressed in the mammalian central nervous system","volume":"87","author":"Weir","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib198","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1615\/CritRevNeurobiol.v11.i2-3.40","article-title":"Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin: a peptide superfamily","volume":"11","author":"Wimalawansa","year":"1997","journal-title":"Crit Rev Neurobiol"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib199","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1021\/bi0014498","article-title":"Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo","volume":"40","author":"Xiao","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib200","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.bone.2005.06.021","article-title":"Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover","volume":"37","author":"Xie","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib201","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.bone.2007.01.007","article-title":"Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass","volume":"40","author":"Xie","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib202","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.neuroscience.2008.04.037","article-title":"Impaired hippocampal synaptic function in secretin deficient mice","volume":"154","author":"Yamagata","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib203","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1210\/endo-118-1-176","article-title":"Insulin-like growth factor I action on rat anterior pituitary cells: suppression of growth hormone secretion and messenger ribonucleic acid levels","volume":"118","author":"Yamashita","year":"1986","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib204","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1054-3589(05)52008-8","article-title":"Inhibition of glucagon secretion","volume":"52","author":"Young","year":"2005","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib205","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1523\/JNEUROSCI.21-18-07063.2001","article-title":"Secretin facilitates GABA transmission in the cerebellum","volume":"15","author":"Yung","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib206","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/10408369009105900","article-title":"The calcitonin gene peptides: biology and clinical relevance","volume":"28","author":"Zaidi","year":"1990","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.pharmthera.2009.07.006_bib207","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.regpep.2007.06.008","article-title":"Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific analogues for PET imaging of breast cancer: in vitro\/in vivo evaluation","volume":"144","author":"Zhang","year":"2007","journal-title":"Regul Pept"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725809001600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725809001600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T19:24:19Z","timestamp":1739301859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725809001600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":207,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0163725809001600"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2009.07.006","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}